About Inventiva

Company Description

We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.

We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. By leveraging these assets and expertise, we are advancing two clinical candidates in two indications, as well as a deep pipeline of earlier stage programs.

Year founded

2011

Served area

Worldwide

Headcount

105

Headquarters

50 Rue de Dijon, 21121 Daix – France

Shareholder information

Shares outstanding

40,873,551

IPO

Feb. 15, 2017

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.